Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694113 | 0.92 | CA1 (0.40) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL3703494 | 0.91 | NFE2L2 (0.33) | HTR6PTGDR2 | |
| SCHEMBL3709951 | 0.89 | CA1 (0.36) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL476288 | 0.84 | COMT (0.41) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL476434 | 0.83 | COMT (0.40) | PTGS2HTR6 | |
| SCHEMBL3695806 | 0.81 | CA1 (0.40) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL476363 | 0.81 | HTR6 (0.39) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL476311 | 0.81 | CA1 (0.35) | CA1CA2CA9PTGS2HTR6 | |
| SCHEMBL476443 | 0.80 | CA1 (0.45) | CA1CA2CA9PTGS2PTGDR2 | |
| SCHEMBL476451 | 0.80 | HTR6 (0.39) | PTGS2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | CA1 975/4885CA2 335/4885CA9 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.